Drug Pricing
Featured Topics
Lead story
Other featured articles
-
Shame Won’t Solve America’s Obesity Crisis: How Congress Can Help
If saving lives is the objective, then logic, clinical evidence and compassion dictate that Medicare should pay for preventing and treating obesity, starting now.
Posted in -
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
Individuals in underserved communities have to travel long distances, well beyond the 30-minute standard, to access clinical trial sites for Aduhelm.
Posted in -
During the Height of the Opioid Epidemic, the Out-of-Pocket Price of Naloxone Increased by Over 500%
A jump in the out-of-pocket price of naloxone has likely made the lifesaving drug too expensive for most uninsured Americans.
Posted in -
Drugmakers Aren’t Driving Inflation. Price Controls Would Hinder Medical Progress
Drug prices have not experienced the major rise in cost like eggs or gasoline, and instituting price controls on drugs would only stifle medical innovation.
Posted in
About this section
High pharmaceutical prices may garner headlines, but innovation must be appropriately incentivized to help solve healthcare’s intractable challenges. The Schaeffer Center connects industry, the academy and government to support the scientific and technological creativity that saves and improves lives — and spurs economic growth.
Our Experts On Drug Pricing
Our Work In Drug Pricing
-
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government
Researchers evaluate prescription drug claims from Medicare Part D beneficiaries to evaluate the current spending distribution.
Categorized in -
The Cantwell-Grassley PBM Bill Is Much Needed But More Can Be Done
The proposed reforms are a helpful start, but could go further in addressing the lack of competition in the U.S. PBM market.
Categorized in -
PBMs Are Inflating the Cost of Generic Drugs. They Must Be Reined In
Anti-competitive practices and a lack of transparency in the generic drug market allow pharmacy benefit managers to profit off patients and payers.
Categorized in -
The FDA Could Do More to Promote Generic Competition: Here’s How
USC-Brookings Schaeffer Initiative experts focus on three areas of FDA authority that could be refined to better promote generic competition: the Citizen Petition mechanism; the approval of so-called complex generic drugs; and the phenomenon known as “parking” under the Hatch-Waxman Act.
-
Schaeffer White Paper Highlights Failures in Generic Drug Market That Cost Patients
A new USC Schaeffer Center paper highlights tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, that are costing patients, employers and the government billions for what should be inexpensive medicines.
Categorized in -
U.S. Consumers Overpay for Generic Drugs
Tactics used by intermediaries in the pharmaceutical distribution system, including pharmacy benefit managers (PBMs) and insurers, are costing patients, employers and the government billions for what should be inexpensive medicines.
Categorized in